| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.kwalitypharma.com | |
| Market Cap | 513.05 Cr. | |
| Enterprise Value(EV) | 572.93 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 11.54 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 42.86 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.25 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 211.00 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.34 | Calculated using Price: 494.45 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.04 Cr. | 10,376,198 Shares |
| FaceValue | 10 | |
| About Kwality Pharmaceuticals Ltd. | ||
| The company ‘Kwality Pharmaceuticals Limited' was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers. | ||
| 1 Day |
|
+4.99% |
| 1 Week |
|
+9.63% |
| 1 Month |
|
+15.06% |
| 3 Month |
|
+1.69% |
| 6 Month |
|
+43.67% |
| 1 Year |
|
+53.84% |
| 2 Year |
|
-1.89% |
| 5 Year |
|
+1077.26% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 4.53 | 6.54 | 14.41 | 16.51 | 23.13 | 20.1 | 28.21 | 99.66 | 10.15 | |
| Return on Capital Employed (%) | 9.69 | 12.3 | 19.56 | 19.17 | 21.89 | 18.46 | 26.35 | 97.93 | 12.27 | |
| Return on Assets (%) | 2.21 | 2.9 | 5.37 | 5.29 | 7.5 | 6.9 | 9.97 | 47.33 | 5.55 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 19 | 22 | 26 | 30 | 37 | 46 | 61 | 181 | 201 | 212 | |
| Non Curr. Liab. | 1 | 3 | 4 | 5 | 8 | 20 | 28 | 21 | 29 | 25 | |
| Curr. Liab. | 17 | 27 | 42 | 62 | 61 | 68 | 78 | 139 | 126 | 119 | |
| Minority Int. | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Equity & Liab. | 37 | 51 | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 355 | |
| Non Curr. Assets | 13 | 13 | 18 | 21 | 30 | 43 | 60 | 113 | 146 | 150 | |
| Curr. Assets | 24 | 38 | 53 | 75 | 75 | 89 | 106 | 228 | 207 | 205 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | |||||||
| Total Assets | 37 | 51 | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 355 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 52 | 74 | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 284 | |
| Other Income | 0 | 0 | 1 | 1 | 1 | 4 | 2 | 4 | 3 | 3 | |
| Total Income | 53 | 75 | 100 | 138 | 167 | 143 | 264 | 460 | 254 | 287 | |
| Total Expenditure | -49 | -69 | -89 | -126 | -151 | -125 | -233 | -285 | -190 | -227 | |
| PBIDT | 4 | 5 | 10 | 12 | 16 | 18 | 30 | 175 | 64 | 60 | |
| Interest | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -3 | -7 | -9 | |
| Depreciation | -1 | -2 | -3 | -3 | -3 | -4 | -6 | -11 | -15 | -19 | |
| Taxation | -1 | -1 | -2 | -3 | -3 | -3 | -6 | -42 | -6 | -4 | |
| Exceptional Items | -17 | -17 | |||||||||
| PAT | 1 | 1 | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 12 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 12 | |
| Adjusted EPS | 1 | 2 | 3 | 4 | 7 | 8 | 15 | 116 | 19 | 12 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | 1 | -3 | 4 | -1 | 14 | 6 | 27 | 61 | 41 | |
| Cash Fr. Inv. | -3 | -1 | -2 | -7 | -6 | -12 | -18 | -23 | -63 | -48 | |
| Cash Fr. Finan. | 3 | 1 | 6 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | |
| Net Change | -1 | 1 | 0 | 2 | -1 | 0 | 0 | 4 | 3 | -6 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 6 | 9 | 3 |
|
Mon, 22 Apr 2024
KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS AMPOULE AND VIAL PRODUCT LINES KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS AMPOULE AND VIAL PRODUCT LINES. DETAILS ATTACHED. |
|
Fri, 12 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Reg 74(5) of SEBI (DP) Regulations for q.e. 31-03-2024 is enclosed herewith |
|
Fri, 12 Apr 2024
Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations 2018 For The Quarter Ended March 31 2024 Certificate under reg 74(5) of SEBI DP regulations for q.e. 31-03-2024 is enclosed herewith |
| Mon, 22 Apr 2024 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
